SCHEMBL2189526

SCHEMBL2189526

C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H]([C]=O)CCC(N)=O)[C@@H](C)O

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PDCD1LG2 Q9BQ51 1/20 0.35
CD274 Q9NZQ7 1/20 0.35
MAGI3 Q5TCQ9 1/20 0.33
TASP1 Q9H6P5 1/20 0.33
DPP4 P27487 1/20 0.33
DPP8 Q6V1X1 1/20 0.33
DPP9 Q86TI2 1/20 0.33
KISS1R Q969F8 3/20 0.33
SIRT2 Q8IXJ6 1/20 0.33
SIRT5 Q9NXA8 1/20 0.33
CTSC P53634 1/20 0.32
OPRM1 P35372 1/20 0.30
OPRD1 P41143 1/20 0.30
OPRK1 P41145 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2638569 0.85 DPP4 (0.42) PDCD1LG2CD274DPP4DPP8DPP9
SCHEMBL2638531 0.85 DPP4 (0.42) PDCD1LG2CD274DPP4DPP8DPP9
SCHEMBL2638683 0.85 DPP4 (0.42) PDCD1LG2CD274DPP4DPP8DPP9
SCHEMBL2638527 0.85 DPP4 (0.42) PDCD1LG2CD274DPP4DPP8DPP9
SCHEMBL2638573 0.85 DPP4 (0.42) PDCD1LG2CD274DPP4DPP8DPP9
SCHEMBL8846990 0.85 DPP4 (0.42) PDCD1LG2CD274DPP4DPP8DPP9
SCHEMBL2637830 0.85 DPP4 (0.42) PDCD1LG2CD274DPP4DPP8DPP9
SCHEMBL2182854 0.85 DPP4 (0.42) PDCD1LG2CD274DPP4DPP8DPP9
SCHEMBL5065724 0.84 SIRT2 (0.36) MAGI3KISS1RSIRT2SIRT5
SCHEMBL6129058 0.84 KISS1R (0.38) KISS1RSIRT2SIRT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190070251-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS 2019-03-07 US disclosed
US-9682153-B2 Polymer conjugates of therapeutic peptides NEKTAR THERAPEUTICS (US) 2017-06-20 US disclosed
US-20160022828-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS 2016-01-28 US disclosed
US-20110171312-A1 MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE NEKTAR THERAPEUTICS (US) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160022828-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP PDCD1LG2 1374/4885CD274 864/4885MAGI3 2187/4885
US-20190070251-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP PDCD1LG2 1374/4885CD274 864/4885MAGI3 2187/4885
US-20110171312-A1 MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE DNPEP, VIP, PTMS PDCD1LG2 1216/4885CD274 1104/4885MAGI3 2737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.